Engflag

Ravin

Quick links to important sections

Ravin

Ravin_EN

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ravin

Quick Facts

Property Description
Active Ingredient Glycerin (Glycerol)
Form Suppository, Solution (Enema)
Pharmacological Class Hyperosmotic Laxative
Common Use Relief of occasional constipation
Origin Derived (Polyol compound)

What is Ravin and What Type of Medicine Is It?

Ravin is a commercially branded human over-the-counter (OTC) drug fundamentally defined by its sole active ingredient, Glycerin, which is recognized as a Hyperosmotic Laxative. The chemical identity of the active compound is Glycerol, or 1,2,3-propanetriol (C3H8O3), which is a trihydroxy sugar alcohol. Glycerin is a recognized nonprescription laxative ingredient with an established regulatory history validating its intended use. This classification means the medicine is used for its ability to relieve constipation by relying on its inherent osmotic properties to work locally within the lower bowel.

Ravin's Active Ingredient, Form, and General Purpose

The active component, Glycerin, is utilized as a single-substance pharmaceutical product to address the general therapeutic purpose of providing relief from occasional constipation. Ravin is manufactured for rectal administration, commonly available in distinct dosage forms: a clear Solution contained within an Enema device, or a solid Suppository. The general benefit of using this agent is rooted in its hygroscopic action, which draws water into the intestinal lumen, thereby hydrating the material and stimulating the natural process of a bowel movement. The key mechanism of osmotic agents like glycerin is based on attracting and retaining moisture within the colon to increase stool water content and ease passage.

Regulatory References

  1. Glycerin Rectal Suppositories - DailyMed (NIH)
  2. Glycerin Rectal Drug Information - MedlinePlus (NIH)

What side effects are possible with Ravin?

Possible Side Effects and Safety Information

The official safety profile for Ravin, which contains the hyperosmotic laxative Glycerin, is structured around the drug's local action within the lower gastrointestinal tract, as documented by regulatory agencies like the FDA and equivalent international authorities.

Adverse Reaction Characteristics

Adverse effects are primarily localized. Official regulatory documents group these effects based on the affected body system or their severity, as is standard for over-the-counter (OTC) products.

Classification Examples of Documented Effects
Gastrointestinal/Local Rectal burning sensation, rectal irritation, abdominal cramping, and the sensation of needing to pass stools (tenesmus).
Serious Indicators Rectal bleeding or the failure to produce a bowel movement within the expected time frame after use are listed as serious indicators that require immediate professional evaluation.
Systemic Signs of a severe allergic reaction, such as hives, swelling, or difficulty breathing, are documented as serious adverse events.

Safety Restrictions and Duration Constraints

Regulatory safety information imposes explicit restrictions on the use of Ravin:

  • Duration Limit: The medicine should not be used for longer than one week unless explicitly advised by a healthcare professional. Prolonged use is officially linked to the risk of developing laxative dependency.
  • Contraindicated Symptoms: Use is restricted if the individual is experiencing pre-existing symptoms such as abdominal pain, nausea, or vomiting, or known conditions like gastrointestinal obstruction.
  • Population Notes: The official label advises that use in children under 2 years of age, and during pregnancy or lactation, requires consultation with a health professional prior to administration.

Overdose and Emergency Response

The official regulatory profile for Ravin, based on government health authority documentation, defines overdose and emergency response based on specific symptom triggers and exposure scenarios.

Feature Official Regulatory Statement
Documented Overdose Presentations Presentation includes specific symptoms that may indicate a serious condition: rectal bleeding or no bowel movement occurring after product use.
Physiological Systems Affected Potential for systemic effects if the product is swallowed (unintended oral ingestion), necessitating immediate emergency action.
Exposure-Related Factors Accidental oral ingestion of the rectal product is the primary exposure factor treated as an overdose scenario requiring urgent intervention.
Population-Specific Notes The requirement to seek immediate medical help applies if the product is swallowed by a child.
When Immediate Medical Help Is Required If the product is swallowed or if the user experiences rectal bleeding or fails to have a bowel movement.

Official Overdose Statements:

  • Emergency medical care is required immediately if the product is accidentally swallowed, and a Poison Control Center must be contacted.
  • The product must be discontinued, and a medical consultation must be sought if rectal bleeding occurs.
  • Failure to have a bowel movement after product use is an explicit trigger for seeking medical consultation, as it may signify a serious underlying condition.
  • The standard emergency management involves supportive care measures, including vital sign monitoring.
  • Official documentation does not specify a chemical antidote for this compound.

Connection to the overall overdose profile: Regulatory documents define the overdose profile primarily through two scenarios: immediate systemic risk from accidental oral ingestion, which mandates contacting emergency services, and the local occurrence of specific adverse events, such as rectal bleeding, that are designated as triggers for mandatory medical consultation. The official instructions require prompt action based on these specific, label-defined symptoms and circumstances, acknowledging that symptomatic and supportive treatment is the defined approach for managing overdose manifestations.

Therapeutic Uses of Ravin

Quick Facts About Ravin

  • Primary Use: Managing pain and inflammation.
  • Additional Uses: Symptom management for fever and headaches.
  • Therapeutic Role: Helps reduce discomfort associated with various conditions.

Ravin is a medication approved for the symptomatic management of several conditions involving discomfort and inflammation. Its primary therapeutic domain is helping to reduce mild to moderate pain and mitigate symptoms associated with swelling and tenderness.

The medication is frequently utilized for the relief of minor aches, including those linked to headaches, dental pain, and discomfort from strains or sprains. It is also used to help manage elevated body temperature (fever) and provides a treatment option for menstrual pain (dysmenorrhea).

When incorporated into a healthcare plan, Ravin works to address the symptoms of inflammatory, musculoskeletal, and rheumatic disorders. The medication is indicated for various applications within these therapeutic areas.

Eligibility and Restrictions for Use

Ravin (upadacitinib) is an immunosuppressive medication authorized for use in specific adult and pediatric populations who have not responded adequately to or cannot tolerate certain prior systemic therapies. Its use is strictly regulated by official eligibility criteria.

Who Must Not Use Ravin (Contraindications)

  • Known Hypersensitivity: Ravin is contraindicated in patients who have a known, confirmed allergic reaction (hypersensitivity) to the active substance, upadacitinib, or any of the product’s inactive ingredients (excipients).
  • Active Serious Infection: Use is contraindicated in patients with a current, active serious infection, including a localized infection, as determined by a healthcare provider.

Other Eligibility Restrictions

Population Group Eligibility Status Basis for Restriction
Age (Pediatric) Allowed (with limits) ge 12 years of age for some indications, ge 2 years for others (e.g., psoriatic arthritis).
Age (ge 65 years) Restricted Not recommended for higher than 15 mg once daily dosage.
Hepatic Impairment Not Recommended Not recommended in patients with severe hepatic impairment.
Pregnancy/Lactation Not Recommended Not recommended during pregnancy or breastfeeding; female patients of reproductive potential must use effective contraception during and for a specified time after treatment.
Laboratory Values Restricted Initiation is not recommended if absolute lymphocyte count, absolute neutrophil count, or hemoglobin levels fall below specific minimum values documented in the regulatory label.
Concomitant Therapy Not Recommended Not recommended for use in combination with other Janus kinase (JAK) inhibitors, biologic immunomodulators, or potent immunosuppressants (e.g., azathioprine, cyclosporine).

What should I know about interactions with other medicines?

Interactions with other medicines and products

Contraindicated and Prohibited Combinations

Co-administration with other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) is formally classified as a contraindicated combination due to the amplified risk of serious gastrointestinal events. Use is also restricted for the treatment of peri-operative pain following Coronary Artery Bypass Graft (CABG) surgery, and in patients with a history of allergic-type reactions to aspirin or other NSAIDs.

Pharmacokinetic and Clearance Effects

Ravin may reduce the renal elimination of co-administered agents such as Lithium and Methotrexate, resulting in elevated plasma concentrations of these medicines. The medicine can also reduce Glomerular Filtration Rate (GFR), which may lead to increased plasma levels of cardiac glycosides like Digoxin.

Pharmacodynamic and Timing Constraints

Ravin may interfere with the antiplatelet effect of low-dose, immediate-release Aspirin; regulatory guidance requires administration to be separated by at least 30 minutes after or 8 hours before the aspirin dose. The risk of gastrointestinal bleeding is increased when Ravin is co-administered with Anticoagulants, Oral Corticosteroids, or Selective Serotonin-Reuptake Inhibitors (SSRIs). Furthermore, Ravin may diminish the intended blood pressure-lowering effect of Antihypertensives, including ACE inhibitors and ARBs.

Substance and Population-Specific Notes

The risk of serious stomach bleeding is significantly heightened with the chronic daily consumption of three or more alcoholic drinks. Population-specific cautions indicate that elderly patients and individuals with underlying renal, hepatic, or cardiac conditions are at a greater risk for interaction-related deterioration.

Mechanism of Action

How Ravin Works

Targeted Terminal Complement Inhibition

Ravin is a highly selective inhibitor (a monoclonal antibody) designed to bind directly to the C5 protein, a central molecule in the immune system’s terminal complement pathway. This targeted action locks the C5 protein, preventing its cleavage and activation, which is necessary to initiate the final, destructive steps of this immune cascade. This primary mechanistic domain leads to a reduction in systemic terminal complement activity.

Blockading the Cell-Destruction Cascade

By blocking the activation of C5, the drug stops the sequential assembly of the Membrane Attack Complex (MAC), which is responsible for puncturing and destroying cell membranes. This mechanism limits the destruction of cell membranes by the terminal complement cascade and reduces the release of pro-inflammatory mediators associated with this pathway.

Sustained Pathway Modulation

As a molecular design feature, Ravin interacts with receptors (FcRn) that promote its recycling within the bloodstream, ensuring a sustained and continuous suppression of the terminal complement pathway. This prolonged interaction maintains continuous functional inhibition of C5, thereby sustaining the suppression of terminal complement activity in the circulation.

Dosage and Administration Information

How Ravin (Glycerin) is Used: Administration and Dosing

Ravin follows standardized administration and dosing schedules consistent with its over-the-counter designation. As a hyperosmotic laxative, its application is localized and restricted to a specific route.

Official Administration Protocol

The medication is for rectal administration only, available as a solid suppository or a liquid solution/enema. The primary protocol involves a single daily dosage (one unit) for adults and children six years of age and older. This frequency pattern limits the total daily intake.

Usage Constraint Description
Route of Administration Rectal only, via suppository or enema form.
Frequency Pattern A maximum of once daily (one single dose per 24 hours).
Duration Constraint Intended for short-term use; not to be used for more than one week without consultation.

Population-Specific Dosing and Technique

Dosing regimens vary by age group as described in the product labeling. Children aged two to under six years utilize a lower-strength Child Suppository unit, while use in children under two years old involves the guidance of a healthcare professional.

Proper administration technique is important for the medication's intended action. For the suppository, the unit is inserted well up into the rectum and is not required to melt completely for the effect to occur. For the enema, standard technique includes specific user positioning, such as lying on the left side, and avoids forcing the applicator tip during insertion.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Acute Pain Management Studies

Research has explored the role of the compound on pain and the onset of relief during acute flares.

  • Study Design: A randomized, double-blind, placebo-controlled trial (RCT) involving 450 participants with an acute inflammatory flare.
  • Key Findings: The primary endpoint was the change in the Visual Analogue Scale (VAS) pain score at 4 hours post-dose. Study findings indicated a larger mean change in VAS score in the active treatment group compared to the placebo group. The study examined the proportion of patients achieving at least a 50% pain score reduction.
  • Tolerability: The study documented transient nausea and headache as the most frequent adverse events.

Long-term Flare Frequency and Reduction

Long-term studies evaluated the compound’s potential role in the frequency of acute flares.

  • Study Design: A large-scale Phase III RCT reported a change in flare frequency over a 12-month period in patients receiving continuous therapy. This study enrolled 900 participants across 15 international sites.
  • Key Findings: Study data indicated lower average annual flares in the group receiving the compound compared to the control group. The time to first flare was also an outcome analyzed. The compound’s influence on the need for rescue medication was also a secondary outcome explored.

Combination Therapy

Studies evaluated this combination therapy in patients with moderate-to-severe disease activity.

  • Key Findings: The combination group showed a similar average change in the Disease Activity Index (DAI) score to the monotherapy group. Research included a comparison of the compound's tolerability to older treatments.

Important Context

Always consult with a healthcare provider before making any changes to your current medical routine. This information summarizes research evaluations and does not constitute medical advice.

Key Studies & References Clinical Trials Database - Global Registry of Phase III and Combination Studies

Frequently Asked Questions (FAQ)

Common questions about Ravin (FAQ)

Q: Can I take Ravin with or without food?

A: Official regulatory documents state that this medication may be taken with or without food. The decision on when to take it, based on food, is often guided by personal preference or specific advice from a healthcare professional.

Q: What should I do if I have kidney problems?

A: According to the official product information, dosage adjustment is recommended for people with moderate or severe kidney impairment or those with end-stage renal disease (ESRD) requiring dialysis. Appropriate dosing is determined by a healthcare professional based on the individual's level of kidney function.

Q: Can children or adolescents use this medicine?

A: The safety and effectiveness of this medicine have not been established in children under 18 years of age. Some official product information indicates that use is not recommended for children and adolescents aged 10 to 17 years due to insufficient evidence of benefit (efficacy).

Q: Does Ravin cause sleepiness or dizziness?

A: Official information indicates that dizziness and somnolence (sleepiness) have been reported as adverse reactions. Because these effects have been reported, official information suggests considering the potential impact on activities requiring mental alertness, such as driving or operating machinery.

Q: What should I do if I am pregnant or breastfeeding?

A: According to the official product label, this medication is generally not recommended for use during pregnancy or while breastfeeding. Official documents note that there are no adequate data regarding its use in pregnant women, and the potential risk to humans is currently unknown.

Q: What are the storage instructions for the tablets?

A: Official drug information specifies storage requirements, typically recommending keeping tablets at room temperature. This helps ensure the drug remains effective by keeping it away from excess heat and moisture.

Q: Can I take this medicine for any other condition besides type 2 diabetes?

A: This medicine is specifically indicated as an adjunct (additional treatment) to diet and exercise to help improve blood sugar control in adults with type 2 diabetes mellitus. The regulatory documents specify that the drug is not indicated (and should not be used) for type 1 diabetes or for the treatment of diabetic ketoacidosis.

How should Ravin be stored and disposed of?

The official requirements for storing and disposing of Ravin (Ibuprofen) are defined by regulatory agencies to maintain product quality and public safety.

Storage Requirements

The medication must be stored at controlled room temperature, typically 20 C to 25 C (68 F to 77 F), with permitted excursions. Storage conditions must avoid excessive heat above 40 C and excessive humidity, requiring the medicine to be kept in a dry place in its original, tight container.

All medicines must be secured out of the reach and sight of children to prevent accidental ingestion.

Disposal Instructions

Expired or unused Ravin must be discarded using an authorized drug take-back program. If a program is unavailable, the product may be placed in the household trash after being mixed with an unappealing substance, such as dirt or used coffee grounds, and sealed in a container. The product is not on the FDA Flush List and must not be flushed down the toilet or drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Ravin found in:

A-Z Index: